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Cross-sectional studies have demonstrated that the brain-derived neurotrophic factor 
(BDNF) Val66Met single-nucleotide polymorphism moderates the association between 
exposure to negative life events and depression outcomes. Yet, it is currently unclear 
whether this moderating effect is applicable to positive life events and if the moderating 
effect is stable over time. To address these gaps in the literature, we examined clinical 
and BDNF genotypic data from a 5-year prospective cohort of 310 primary care attend-
ees. Primary care attendees were selected based on existence of depressive symptoms 
at screening. Depressive symptoms were assessed at baseline and annually for 5 years 
post-baseline using the Primary Care Evaluation of Mental Disorders Patient Health 
Questionnaire-9 (PHQ-9). Linear mixed models assessed differences in depressive 
symptom severity over the 5-year follow-up period by BDNF Val66Met and history of 
life events, both negative and positive. Analysis identified a novel three-way interac-
tion between the BDNF Val66Met polymorphism, history of severe childhood abuse, 
and time. Post hoc analysis stratified by time showed a two-way interaction between 
Val66Met and severe childhood abuse at baseline that was not detectable at any other 
time point. An interaction between Val66Met and positive life events was not detected. 
Our longitudinal results suggest that the BDNF Val66Met polymorphism moderates the 
depressive symptom severity experienced by those with a history of severe childhood 
abuse but does so in a time-dependent manner. Our results further support the notion 
that gene–environment–depression interactions are dynamic and highlight the impor-
tance of longitudinal assessment of these interactions. Given these novel longitudinal 
findings; replication is required.
Keywords: depression, gene–environment, brain-derived neurotrophic factor, childhood adversity, stressful life 
events, longitudinal cohort
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inTrODUcTiOn
The etiologies of depression are poorly understood, with the 
most recent etiological theories focusing on gene–environment 
interactions. Depressive phenotypes have long been associated 
with exposure to negative events, yet phenotypic variation is 
evident, with individuals exposed to the same environmental 
stress either not developing depressive symptoms or developing 
a range of symptom severity (1). This phenotypic variation is 
the basis of the diathesis–stress psychological framework (2), 
which suggests individuals possess “risk” factors (e.g., genetic 
variants), which make them more vulnerable to developing 
psychological symptoms when exposed to an adverse event. 
Historically, the diathesis–stress framework has guided research 
into gene–environment interactions. However, an emerging 
alternative framework is that of differential susceptibility. The 
differential susceptibility framework postulates that tradition-
ally defined “risk” factors may better be defined as “phenotypic 
plasticity” factors in that individuals carrying these factors are 
more sensitive to both positive and negative environmental 
influences (3).
Environmental influences consistently linked to depression 
include adverse childhood events (4, 5) and current domestic 
abuse among women (6). However, environmental stress alone 
has been identified as insufficient to cause depression (7), 
emphasizing the gene–environment hypothesis. Current lit-
erature clearly identifies numerous genetic variants associated 
with mediating the differential response to negative life events 
in the development of depression (8). Among these genes is 
the brain-derived neurotrophic factor (BDNF), specifically the 
Met  allele in the Val66Met single-nucleotide polymorphism 
located in the coding region of exon 2 (rs6265 – A66G) (8). 
BDNF is a pro-survival factor, involved in brain cell survival 
and proliferation (8) and has also been suggested to affect neu-
ronal plasticity (9). Depressed individuals are shown to have 
decreased serum BDNF levels compared to controls (10–12) 
and carriers of the BDNF rs6265 Met allele show a reduction in 
BDNF activity (13).
Studies examining the interaction between BDNF genetic vari-
ation and stressful life events have reported conflicting results. A 
number of studies identified an association between the BDNF 
Met allele and greater depressive symptom severity in the context 
of childhood abuse or adult abuse (14). Other studies reported 
that BDNF moderates the response to some, but not all, forms 
of abuse (15, 16). While two large studies, one a cross-sectional 
study (17) and another a case–control study (18) reported no 
moderating effect of BDNF genetic variation on the association 
between stressful life events and depressive symptoms.
In light of these conflicting results, the role of BDNF genetic 
variation in moderating depressive symptoms in the context of 
stressful life events remains unclear. In addition, the role BDNF 
plays in moderating depressive symptom severity in the context 
of life events over time is not clear. As such, we examined whether 
the BDNF Val66Met polymorphism moderated the relationship 
between life events (negative and positive) and depressive symp-
tom severity in a 5-year prospective cohort of 310 primary care 
attendees.
MaTerials anD MeThODs
Participants
Participants were recruited from the Diagnosis, Management 
and Outcomes of Depression in Primary Care (diamond) study, 
an ongoing prospective cohort that commenced in 2005 (19). 
The diamond study aims to document the experiences, health 
outcomes, treatment, and service usage of primary care attendees 
identified as having clinically relevant depressed mood at screen-
ing; with patients recruited from 30 rural and metropolitan 
general practices randomly recruited in Victoria, Australia (19). 
Primary care patients were eligible for the diamond cohort if 
they were: (a) aged 18–75 years, (b) able to read English, (c) not 
terminally ill, (d) did not reside in a nursing home, and (e) scored 
16 or higher on the Center for Epidemiologic Studies Depression 
Scale (CES-D). Participants were assessed annually using postal 
surveys as well as computer-assisted telephone interviews. In 2011 
(cohort year 6), participants enrolled in the cohort were invited to 
provide a saliva sample for DNA extraction and genotyping. All 
procedures were conducted in accord with principles expressed 
in the Declaration of Helsinki and obtained approval from the 
University of Melbourne Human Research Ethics Committee 
(Ethics ID 1135247.1).
Depressive symptom Measures
Longitudinal depressive symptoms were assessed at baseline 
and annually for 5  years thereafter using the self-administered 
Primary Care Evaluation of Mental Disorders Patient Health 
Questionnaire-9 (PHQ-9) (20). The PHQ-9 is based directly 
on the nine signs and symptoms of major depressive disorder 
as described in the Diagnostic and Statistical Manual of Mental 
Disorders-IV (DSM-IV) (21) and has been validated to screen 
and monitor depression severity in the primary care setting (22). 
The PHQ-9 asks respondents to rate their symptoms over the past 
2  weeks and is scored on a scale of zero (“not at all”) to three 
(“nearly every day”) for each item with a range of 0–27 (20). Scores 
of 5, 10, 15, and 20 on the PHQ-9 represent cut-points for mild, 
moderate, moderately severe, and severe depression, respectively 
(20). DSM-IV criteria (23) for major depressive disorder was 
assessed using the Composite International Diagnostic Interview 
(CIDI) Auto version 2.1 (24) by a trained research assistant.
childhood abuse
At baseline exposure to physical and sexual childhood abuse 
was measured using the Child Maltreatment History Self-Report 
(CMHSR) (25). The CMHSR consists of 11 items, 7 pertaining 
to physical abuse and 4 to sexual abuse. The physical abuse ques-
tions have a four-point response option (never, rarely, sometimes, 
often), whereas the sexual abuse questions have a yes/no response 
option. Severe abuse was defined using the scoring algorithm 
previously described by Macmillan and associates (25).
Partner abuse
History of partner abuse in adulthood was measured using a 
history of partner fear as a proxy marker. This was done because 
the available composite abuse scale (CAS) in our cohort has 
not been validated in males as well as to minimize the risk of 
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under-reporting associated with the CAS and to reflect the 
importance on an individual’s perception in the experience of 
abuse (26).
life events
At baseline, participants completed a 13-item life events ques-
tionnaire adapted from the Life Experiences Scale and Life 
Events Questionnaire (27, 28). A full list of events measured is 
displayed in Table S1 in Supplementary Material. For each life 
event, participants were asked to indicate whether or not they 
experienced the life event in the past 12 months and if so, what 
impact the event had on them. There were six possible responses 
for each life event: (1) No, I have not experienced this event in 
the past 12 months; (2) Yes, and it has had an extremely negative 
impact on me; (3) Yes and it has had a slightly negative impact 
on me; (4) Yes but it has had no impact on me; (5) Yes and it 
has had a slightly positive impact on me; (6) Yes and it has had 
an extremely positive impact on me. In this study, presence of 
a positive event was defined as one or more events reported as 
slightly or extremely positive. Presence of a negative event was 
defined as one or more events reported as slightly or extremely 
negative.
Potential confounding Variables
At baseline, potential confounding factors, including demograph-
ics, smoking status, quality of life (29), and self-rated health status 
(30) were assessed. Panic and other anxiety syndromes were also 
assessed using the anxiety module of the PHQ (22). Alcohol and 
drug abuse/dependence (i.e., cannabis, opioid, sedative, cocaine, 
amphetamine, hallucinogens, inhalants) was assessed using the 
CIDI Auto version 2.1 (24). At each assessment point, the use 
of antidepressants, anxiolytics, and antipsychotics, as well as 
self-reported visits in the past 12 months to a psychiatrist and/or 
psychologist were also assessed.
Dna extraction and genotyping
DNA extraction and genotyping details have previously been 
published (31). In brief, DNA was recovered from stabilized saliva 
samples and the rs6265 polymorphism was genotyped as part of 
a larger genotyping project with the Sequenom MassARRAY 
MALDI-TOF genotyping system (Sequenom Inc., San Diego, 
CA, USA). To detect for the presence of population stratification, 
60 unlinked ancestry-informative markers (AIMs; Table S2 in 
Supplementary Material) representing the three HapMap phase 
III populations (Northern/Western European, Han Chinese, and 
Yoruba in Nigeria) were also genotyped (32).
statistical analysis
Chi-square analysis of BDNF genotype was used to detect 
departures from Hardy–Weinberg equilibrium. Due to the low 
number of Met/Met carriers (n = 9), individuals who carried the 
Met allele (Val/Met or Met/Met) were compared to homozygous 
Val carriers. To estimate the presence of population stratification, 
the 60 AIMs were used to assign each participant to the HapMap 
ancestral group (Northern/Western European, Han Chinese, and 
Yoruba in Nigeria) for which they carried the greatest proportion 
of that population’s AIMs.
Linear mixed models were used to determine trajectory 
differences in PHQ-9 depressive symptom severity over the 
5-year follow-up period by genotype and abuse/life event 
type. The mixed models approach enables use of all repeated 
measurements, accounts for clustering of participants within 
primary care sites, and provides unbiased estimates in the pres-
ence of missing data. Prior to creation of interaction terms and 
modeling, genotypes, abuse, and life event variables as well as 
covariates were centered (33). Potential covariates were assessed 
for their association with each of the abuse/life event types and 
genotypes using chi-square, Fisher’s exact, or analysis of vari-
ance tests, depending on the variable structure. Covariates with 
p-values ≤0.05 were retained for adjusted analysis (Table S3 in 
Supplementary Material).
The unadjusted model included fixed effects of time, 
genotype, abuse/event, and a time ×  genotype, time ×  abuse/
event, genotype ×  abuse/event, and time ×  genotype ×  abuse/
event interaction terms. Random effects included individual, 
primary care site, intercept (PHQ baseline score), and slope 
(time). Unadjusted models that returned significant main effects 
(p < 0.05) were then adjusted for covariates to account for any 
bias from baseline characteristics. Adjusted models included 
relevant covariates as well as covariate × time, covariate × geno-
type, and covariate  ×  abuse/event type interaction terms as 
previously recommended (34). Covariance models used for the 
random and repeated effects were unstructured and first-order 
autoregressive, respectively.
Adjusted models were then refined using a backward stepwise 
penalized likelihood model selection strategy by starting with 
the most complex model and removing the term with the larg-
est p-value above 0.05 using unrestricted maximum likelihood 
estimations. If removal of a covariate term increased the Bayesian 
information criterion (BIC) compared to previous more complex 
model the covariate was retained. Missing data of longitudinal 
measurements were assumed missing at random. All analyses 
were performed using SPSS 21.0 (IBM, Armonk, NY, USA).
resUlTs
sample characteristics
A total of 789 participants were recruited into the diamond cohort 
of whom 498 were enrolled at the time of DNA collection (cohort 
year 6) and 344 (69%) consented and returned a DNA sample. 
Individuals missing genotype data (n = 22) or abuse data (n = 13) 
were excluded. A total sample of 310 participants was included 
in the analysis (Table 1). Genotype frequencies for BDNF rs6265 
were 67% Val/Val, 33% Met carriers (30% Val/Met and 3% Met/
Met) and were in Hardy–Weinberg equilibrium (p = 0.768). All 
participants were of Northern/Western European (CEU) ancestry 
based on 60 unlinked AIMs (Figure 1).
Unadjusted Findings
Unadjusted linear mixed models for the BDNF rs6265 genotype 
across the abuse and life event types are summarized in Table 2. 
A two-way interaction was not found between BDNF rs6265 and 
positive events (F1, 307 = 0.12, punadjusted = 0.728) or BDNF rs6265 
and negative events (F1, 307 =  0.04, punadjusted =  0.844). However, 
FigUre 1 | ancestry estimation of study sample. Participants were 
assigned to the HapMap ancestral group (Northern/Western European, CEU; 
Han Chinese, CHB; or Yoruba in Nigeria, YRI) for which they carried the 
greatest proportion of that population’s ancestry-informative markers.
TaBle 1 | Participant characteristics (n = 310).
Baseline variables
Demographics
Age, mean (SD) years 48.9 (11.9)
Sex, % (n) female 71 (220)
English as first language, % (n) 99 (307)
Northern European genetic ancestry, % (n) 100 (310)
Depression history
DSM-IV major depressive disorder, % (n)a 49.2 (149)
Relative with a history of depression, % (n)b 75.4 (193)
Co-morbid substance use
Smoker, % (n)c 23.9 (74)
Alcohol abuse/dependence, % (n)a 13 (39)
Substance abuse/dependence (excludes alcohol), % (n) – 301 6.3 (19)
Medication use
Antidepressant, % (n) 40.6 (126)
Anxiolytic, % (n) 9.7 (30)
Antipsychotic, % (n) 5.5 (17)
Sedative, % (n)c 31.1 (96)
St John’s Wort, % (n)c 9.4 (29)
Visited counselor/psychologist/psychiatrist past  
12 months, % (n)
33.2 (103)
Self-rated health, % (n) good to excellent 63.5 (197)
Education, % (n)c
Completed year 12 or less 47.3 (147)
Diploma or certificate 25.2 (78)
Bachelor degree or higher 27.2 (84)
Managing on available income, % (n)d
Easily/not too bad 48.1 (148)
Difficult some of the time 35.7 (110)
Difficult all of the time/impossible 16.2 (50)
WHO Quality of Life and Functioning
Environmental context, mean (SD) 64.2 (13.1)
Social context, mean (SD) 49.7 (23.8)
Severe childhood abuse, % (n)
Sexual 12.9 (40)
Physical 12.9 (40)
Either or both – sexual and/or physical 39 (121)
History of partner fear, % (n) 33.2 (103)
Life events in past 12 months, % (n)
At least one positive 25.8 (80)
At least one negative 81.9 (254)
an = 301.
bn = 256.
cn = 309.
dn = 308.
WHO, World Health Organization.
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a two-way interaction was detected between BDNF rs6265 and 
severe childhood abuse (F1, 307 = 4.6, punadjusted = 0.031) and a three-
way interaction was observed between the BDNF rs6265 genotype, 
severe childhood abuse, and time (F1, 299 = 5.4, punadjusted = 0.021).
covariate-adjusted Findings
Only the three-way interaction survived adjustment for covari-
ates (F1, 292 =  4.9, pcovariate adjusted =  0.027) (Table  3; Table S4 in 
Supplementary Material). Figure  2 shows Met  allele carriers 
with a history of severe childhood abuse had a significantly 
greater reduction in depressive symptom severity over the 5-year 
follow-up period compared to their Val/Val carrying counter-
parts. Post hoc analysis stratified by time showed the two-way 
interaction between BDNF rs6265 and severe childhood abuse 
was present at baseline (F1, 297 =  5.4, punadjusted =  0.021) but no 
other time points (Figure  3). Importantly, further post  hoc 
analyses suggested this time-dependent effect was not due to 
differential receipt of psychosocial (i.e., visits to counselor, 
psychologist, or psychiatrist) or pharmacological (i.e., antide-
pressant, anxiolytic, or antipsychotic) therapy over the 5-year 
study period (Figures 4 and 5).
DiscUssiOn
We demonstrated a novel three-way interaction between the 
BDNF Val66Met polymorphism, a history of severe childhood 
abuse and time. This interaction withstood adjustment for key 
covariates and could not be attributed to differential receipt of 
psychosocial or pharmacological therapy. Previous studies have 
showed the BDNF Val66Met polymorphism moderates the rela-
tionship between history of childhood adversity and depression 
outcomes (15, 35, 36). Our longitudinal results not only support 
these previous findings but also suggest the moderating effect 
conferred by the BDNF Val66Met polymorphism may not be 
stable over time. In fact, we showed the presence of the inter-
action between BDNF rs6265 and severe childhood abuse was 
dependent on the time at which it was assessed; suggesting time 
as a key factor when testing gene–environment interactions.
The stability of gene–environment–depression interactions 
over time has only recently been described (37) but to our knowl-
edge the current study is the first to demonstrate that these inter-
actions may not be stable over time. Demonstrating the stability 
of a gene–environment interaction is critical to our conceptual 
and clinical understanding of depression and related outcomes. 
For example, at baseline, our analysis detected an interaction that 
TaBle 3 | Type iii fixed effectsa for terms included in the final covariate-adjusted linear mixed model.
Parameter Degrees of Freedom F p
numerator Denominator
Intercept 1 310.128 356.731 0.000
Time 1 291.276 16.695 0.000
Genotype – rs6265 1 333.991 0.804 0.371
Severe child abuse 1 332.223 1.897 0.169
rs6265 × time 1 291.919 1.753 0.187
Severe child abuse × time 1 292.359 0.018 0.895
rs6265 × severe child abuse 1 305.182 2.786 0.096
rs6265 × severe child abuse × Time 1 292.215 4.925 0.027
DSM-IV Depression diagnosis 1 317.757 33.355 0.000
DSM-IV Depression diagnosis × Time 1 290.903 5.853 0.016
DSM-IV Depression diagnosis × rs6265 1 297.564 0.032 0.858
DSM-IV Depression diagnosis × severe child abuse 1 297.116 0.205 0.651
Self-rated health 1 307.656 38.684 0.000
Self-rated health × time 1 291.349 5.061 0.025
Self-rated health × rs6265 1 296.148 0.334 0.564
Self-rated health × severe child abuse 1 296.054 0.136 0.712
DSM IV substance abuse/addiction 1 306.156 4.014 0.046
DSM IV substance abuse/addiction × time 1 289.680 0.041 0.839
DSM IV substance abuse/addiction × rs6265 1 294.717 3.176 0.076
DSM IV substance abuse/addiction × severe child abuse 1 294.647 0.470 0.493
WHOQOL Social 1 300.581 18.361 0.000
WHOQOL Social × rs6265 1 299.536 3.026 0.083
WHOQOL Social × severe child abuse 1 297.433 1.061 0.304
aDependent variable: PHQ depressive symptom severity.
Bolded values indicate p < 0.05.
TaBle 2 | general linear mixed model parameter p-values for main and interaction effects of BDnF rs6265 genotype, abusive experiences, and life 
events on 60-month depressive symptom trajectories (n = 310).
Unadjusted p-values for Type iii fixed effects*
event type in model BDnF  
rs6265
event  
type
Time rs6265 ×  
event type
rs6265 ×  
time
event  
type × time
rs6265 ×  
event type × time
History of severe child abuse 0.757 0.001 0.001 0.031 0.084 0.482 0.021
History of partner fear 0.777 0.001 0.001 0.090 0.332 0.104 0.636
Life events
Positive 0.899 0.147 0.001 0.728 0.541 0.026 0.473
Negative 0.920 0.008 0.001 0.844 0.316 0.395 0.894
Bolded values indicate p < 0.05.
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is consistent with the differential susceptibility framework (3) in 
that Met allele carriers reported fewer depressive symptoms in the 
absence of severe childhood abuse and greater depressive symp-
toms in the presence of a history of severe childhood abuse, com-
pared to Val/Val individuals who had similar depressive symptom 
severity regardless of their history of childhood abuse. However, 
over the course of 5 years, this interaction was gradually attenu-
ated and support for the differential susceptibility framework 
was diminished. Furthermore, the presence of a time-dependent 
interaction may in part explain the sub-optimal reproducibility 
of BDNF by environment interactions in previous cross-sectional 
studies. Although other explanations for this interaction effect 
instability likely exist, we ruled out many of these explanations 
(e.g., therapy exposure) in our analyses. Nevertheless, further 
longitudinal examinations of BDNF by environment interactions 
are required to validate our findings.
Potential Mechanism(s)
The mechanism(s) by which the BDNF rs6265 polymorphism 
moderates the relationship between severe childhood abuse 
and depressive symptom severity in adulthood is unclear and 
is beyond the scope of this study. However, previous studies 
have shown BDNF gene expression and serum protein levels 
are decreased in depressed individuals compared to healthy 
controls (10–12) and are also decreased in individuals with the 
Met  allele (13), albeit in healthy individuals Val/Val carriers 
had decreased BDNF levels (38). Nevertheless, there is mod-
est evidence for a link between peripheral BDNF levels and 
depressive symptoms. Importantly, a number of studies have 
shown that serum BDNF levels increase with administration 
of antidepressant medication (39), which is negatively corre-
lated with depressive symptom severity (10, 11). Additionally, 
Alder and Thakker-Varia (9) suggest that BDNF plays a role 
FigUre 3 | interaction effect of severe child abuse and BDNF rs6265 genotype by time point. Time point zero represents baseline, measured annually from 
baseline. Points and associated SE bars represent predicted values based on the final covariate-adjusted model. PHQ-9 = Primary Care Evaluation of Mental 
Disorders Patient Health Questionnaire-9.
FigUre 2 | interaction effect of severe childhood abuse and BDNF Val66Met genotype on 5-year depressive symptom trajectories. Baseline 
represented by time point 0, annual assessment thereafter. Points and associated SE bars represent predicted values based on the final covariate-adjusted model. 
PHQ-9 = Primary Care Evaluation of Mental Disorders Patient Health Questionnaire-9.
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in neuronal plasticity, particularly emotional processing 
networks that are compromised in depression. However, 
further research into the effects of BDNF on neuroplasticity 
and neurodevelopment using post-mortem brain tissue and 
neuroimaging cohorts with childhood abuse exposure and 
depressive symptom data are needed before firm conclusions 
FigUre 4 | longitudinal measurements of medication usage by percent of individuals reportedly taking the medication by genotype and history of 
severe child abuse.
7
Webb et al. BDNF, Child Abuse, and Depressive Symptoms
Frontiers in Psychiatry | www.frontiersin.org August 2016 | Volume 7 | Article 151
can be made on the moderating mechanisms by which BDNF 
genotypic variation acts.
strengths and limitations
This study has several notable strengths, including the longitu-
dinal study design, comprehensive covariate adjustment, and 
centering of data. However, a number of limitations should be 
acknowledged. First, the assessment of environmental expo-
sures and self-reporting of abuse is limited and subject to bias. 
Specifically, within the childhood abuse group, only those who 
had experienced severe childhood abuse either physical or sexual 
were included in analysis. Emotional abuse or neglect experi-
enced during childhood has also been associated with depressive 
symptoms (40) yet were not considered in this study. Validity of 
self-reporting has also been questioned due to significant recall 
bias, often resulting in under-reporting of abuse (41) in both 
reporting stressful life events and recalling adverse childhood 
experiences (41, 42). Thus, our findings may represent a conserva-
tive estimate, which would dilute the interaction effect within 
the sample population and could contribute to negative results. 
Second, our measures of positive environmental exposure (e.g., 
positive life events) were sub-optimal and only capture adulthood 
experiences. Measures of “positive” exposures in childhood, 
such as maternal attachment or parental engagement, would be 
ideal but were not available. Third, BDNF serum levels were not 
measured in our study. Given that BDNF serum levels have been 
negatively correlated with depressive symptoms (39) and carriage 
of the Met allele (13), future study into BDNF genetic variation as 
a moderator of life events on depressive symptoms should include 
measurement of BDNF serum levels. Finally, rather than diag-
nosis of major depressive disorder, depressive symptom severity 
was the primary outcome measure limiting extrapolation and 
comparison to similar studies. However, the PHQ-9 scale consists 
of the nine diagnostic criteria outlined in DSM-IV and has been 
validated as a tool for assessing depressive symptom trajectories 
(20) and may translate better into the primary care setting.
cOnclUsiOn
We have identified a novel three-way interaction between BDNF 
genetic variation, a history of severe childhood abuse, and time 
that was associated with depressive symptom severity. This 
interaction highlights the dynamic nature of gene–environ-
ment–depression interactions and the importance of longitudinal 
assessment of these interactions. Discrepancies among previous 
study results could be associated with not just study design, but 
also time of analysis. Given this is the first longitudinal study of 
its kind; replication of results is needed.
aUThOr cOnTriBUTiOns
JG conceived and established the diamond cohort. CB, IE, and JG 
conceived the current study design and analysis. MP project man-
aged the data collection. CW and CB conducted the analysis and 
FigUre 5 | longitudinal measurements of psychosocial treatment by percent of individuals reported as having seen a psychiatrist, psychologist, or 
counselor once or more in the preceding 12 months, by genotype and history of severe child abuse.
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